Testosterone replacement therapy: clinical considerations
- PMID: 38229462
- DOI: 10.1080/14656566.2024.2306832
Testosterone replacement therapy: clinical considerations
Abstract
Introduction: As an increasingly popular therapeutic option, testosterone replacement therapy (TRT) has gained significant notoriety for its health benefits in indicated populations, such as those suffering from hypogonadism.
Areas covered: Benefits such as improved libido, muscle mass, cognition, and quality of life have led to widened public interest in testosterone as a health supplement. No therapy exists without side effects; testosterone replacement therapy has been associated with side effects such as an increased risk of polycythemia, benign prostate hypertrophy (BPH), prostate cancer, gynecomastia, testicular atrophy, and infertility. Testosterone replacement therapy is often accompanied by several prophylactic co-therapies aimed at reducing the prevalence of these side effects. Literature searches for sections on the clinical benefits and risks associated with TRT were performed to include clinical trials, meta-analyses, and systematic reviews from the last 10 years.
Expert opinion: Data from clinical studies over the last decade suggest that the benefits of this therapy outweigh the risks and result in overall increased quality of life and remission of symptoms related to hypogonadism. With this in mind, the authors of this review suggest that carefully designed clinical trials are warranted for the investigation of TRT in symptomatic age-related hypogonadism.
Keywords: TRT; Testosterone; hypogonadism; prostate; testosterone replacement therapy.
Similar articles
-
EMAS position statement: Testosterone replacement therapy in older men.Maturitas. 2023 Dec;178:107854. doi: 10.1016/j.maturitas.2023.107854. Epub 2023 Oct 15. Maturitas. 2023. PMID: 37845136
-
Late-life onset hypogonadism: a review.Clin Geriatr Med. 2010 May;26(2):197-222. doi: 10.1016/j.cger.2010.02.003. Clin Geriatr Med. 2010. PMID: 20497841 Review.
-
[Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].Urologe A. 2009 May;48(5):516-22. doi: 10.1007/s00120-009-1954-z. Urologe A. 2009. PMID: 19296069 Review. German.
-
Testosterone Therapy: What We Have Learned From Trials.J Sex Med. 2020 Mar;17(3):447-460. doi: 10.1016/j.jsxm.2019.11.270. Epub 2020 Jan 9. J Sex Med. 2020. PMID: 31928918 Review.
-
Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.Am J Physiol Endocrinol Metab. 2015 Jun 15;308(12):E1035-42. doi: 10.1152/ajpendo.00111.2015. Epub 2015 Apr 21. Am J Physiol Endocrinol Metab. 2015. PMID: 25898953 Free PMC article. Review.
Cited by
-
Supporting Transgender, Nonbinary, and Gender Diverse Youth During Solid Organ Transplantation.Pediatr Transplant. 2025 Feb;29(1):e14864. doi: 10.1111/petr.14864. Pediatr Transplant. 2025. PMID: 39620485 Free PMC article. Review.
-
Biochemical Hypogonadism in Aging Testicular Cancer Survivors: A Clinical Challenge.Eur Urol Open Sci. 2025 Jan 17;72:10-16. doi: 10.1016/j.euros.2024.12.010. eCollection 2025 Feb. Eur Urol Open Sci. 2025. PMID: 39897186 Free PMC article.
-
Effects of Testosterone Replacement Therapy on Metabolic Syndrome in Male Patients-Systematic Review.Int J Mol Sci. 2024 Nov 14;25(22):12221. doi: 10.3390/ijms252212221. Int J Mol Sci. 2024. PMID: 39596286 Free PMC article.
-
Pubertal induction therapy in pediatric patients with Duchenne muscular dystrophy.J Pediatr Endocrinol Metab. 2025 Mar 12;38(8):781-787. doi: 10.1515/jpem-2025-0061. Print 2025 Aug 26. J Pediatr Endocrinol Metab. 2025. PMID: 40068954 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials